Idiopathic Thrombocytopenic Purpura (ITP) is an autoimmune disease characterised predominantly by an antibody mediated destruction of platelets. Few treatment options are available for ITP like corticosteroids, IV immunoglobulins, splenectomy, rituximab, danazole and cyclophosphamide. All these treatment options work by reducing the destruction of platelets by antibody. However recent evidence suggests that production of platelet is reduced in 75% of thrombocytopenic patient with ITP. Romiplostim is a novel thrombopoetin receptor agonist approved by USFDA in August 2008 that increases the platelet count in ITP patients unresponsive to corticosteroids, immunoglobulins or splenectomy. Romiplostim is not currently available in India. The addition of Romiplostim in the treatment options for ITP will surely improve the outcomes in ITP patients.
|Number of pages||7|
|Journal||Journal of Clinical and Diagnostic Research|
|Publication status||Published - 2009|
Patel, H., Patel, N., Vyas, A., Patel, M., & Pandey, S. (2009). Romiplostim: A novel c-Mpl/CD110 receptor ligand for the management of idiopathic thrombocytopenic purpura. Journal of Clinical and Diagnostic Research, 3(4), 1690-1696.